The NP resin portfolio, indicated by its UL746G-certified prefix, equips manufacturers across industries to meet increasingly stringent regulatory and performance standards
These building blocks are essential to modern therapeutics, including fast-growing GLP-1 treatments for weight loss and diabetes
Implementing PFAS testing in the early development stages allows medical device manufacturers to prepare for potential regulatory updates
The technology is intended to support imaging-based training, protocol optimisation and surgical planning
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
The deliveries bring the innovative medicine to communities heavily impacted by HIV just five months after U.S. FDA approval
Paxton alleges the companies marketed Plavix as a reliable defense against heart attacks, strokes, and blood clots while failing to disclose evidence that the drug could be ineffective or virtually useless for many people
The company says the innovation delivers stronger moisture protection for highly sensitive drug molecules
ALBIS will present a selection of advanced materials from its broad healthcare portfolio
Subscribe To Our Newsletter & Stay Updated
